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Micro- and nanometer-size particles have become
popular candidates for cancer vaccine adjuvants.
However, the mechanism by which such particles
enhance immune responses remains unclear. Here,
we report a porous silicon microparticle (PSM)-
based cancer vaccine that greatly enhances cross-
presentation and activates type I interferon (IFN-I)
response in dendritic cells (DCs). PSM-loaded anti-
gen exhibited prolonged early endosome localiza-
tion and enhanced cross-presentation through both
proteasome- and lysosome-dependent pathways.
Phagocytosis of PSM by DCs induced IFN-I re-
sponses through a TRIF- and MAVS-dependent
pathway. DCs primed with PSM-loaded HER2 anti-
gen produced robust CD8 T cell-dependent anti-tu-
mor immunity in mice bearing HER2+ mammary
gland tumors. Importantly, this vaccination activated
the tumor immune microenvironment with elevated
levels of intra-tumor IFN-I and MHCII expression,
abundant CD11c+ DC infiltration, and tumor-specific
cytotoxic T cell responses. These findings highlight
the potential of PSM as an immune adjuvant to
potentiate DC-based cancer immunotherapy.INTRODUCTION
Cancer immunotherapy has gained a high level of attention lately
thanks to the recent FDA approval of a dendritic cell (DC)-based
metastatic prostate cancer therapy (Provenge) and checkpoint
blockade antibodies (e.g., anti-CTLA4 and anti-PD1) for late-stage cancer treatment (Hodi et al., 2010; Postow et al., 2015;
Sharma et al., 2011). Despite these advances, however, a com-
plete response to cancer immunotherapy remains rare due to
multiple factors, including inefficient vaccine delivery, defective
antigen cross-presentation in tumor tissues, infiltration of sup-
pressive immune cells (e.g., regulatory T cells [Tregs] and
myeloid-derived suppressor cells [MDSCs]), and an immuno-
suppressive cytokine milieu (Dougan and Dranoff, 2009).
Approaches to reverse the immunosuppressive tumor microen-
vironment are anticipated to have a significant impact on cancer
immunotherapy (Gajewski et al., 2013b).
Innate immunity is a major component of tumor immunity, and
proper activation of innate immune cells by recognizing tumor
antigens and danger signals from tumor cells ensures efficient
adaptive immunity against cancer (Dougan and Dranoff, 2009).
Thus, factors that bridge innate immunity and adaptive immunity
can be targeted for cancer immunotherapy. DCs function as pro-
fessional antigen-presenting cells (APCs) by surveying and pro-
cessing antigen to T cells, and the antigen presentation process
often requires subcellular antigen delivery and innate immune
signaling. A previous study reported that class I antigen is pro-
cessed in early endosomes, and that Toll-like receptor 4
(TLR4)-MyD88 activity is required for proper relocation of the
transporter associated with antigen processing (TAP) protein
(Burgdorf et al., 2008). However, that study focused on soluble
antigen cross-presentation, and whether the same mechanism
can be applied to other forms of antigens, such as particulate an-
tigens, remains unknown.
Innate immune stimuli such as TLR ligands often serve as
immune adjuvants to enhance DC-based immune responses
(Coffman et al., 2010). TLR activation stimulates downstream
pathways, such as the NF-kB and MAPK signaling pathways,
to induce proinflammatory cytokines (Kawai and Akira, 2011).
These cytokines further induce the expression and transloca-
tion of antigen-presenting molecules and promote antigenCell Reports 11, 957–966, May 12, 2015 ª2015 The Authors 957
Figure 1. PSM-Loaded Antigen Was Efficiently Internalized by DCs
through Phagocytosis and Macropinocytosis
(A) Representative microscopic views of DCs internalizing PSM particles
loaded with OVA-FITC nanoliposomes. Upper: DC2.4 cells; lower: BMDCs.
Scale bar, 25 mm.
(B) A representative transmission electron microscopy picture showing the
vesicular structure around a PSM/OVA particle inside the DC. Upper: 5,0003;
scale bar, 4 mm. Lower: 50,0003; scale bar, 0.5 mm.
(C) DC uptake of PSM/FITC-OVA in the presence of the phagocytosis inhibitor
cytochalasin D.
(D) DC uptake of PSM/FITC-OVA in the presence of the macropinocytosis
inhibitor amiloride.
(E) IL-2 production by B3Z cells after co-incubation with DCs pretreated for
3 hr with different concentrations of soluble OVA or PSM/OVA.
(F) IL-2 production by B3Z cells after co-incubation with DCs that were primed
with 50 mg/ml soluble OVA or PSM/OVA followed by fixation at different time
points.
(G) IL-2 production by B3Z cells after co-incubation with DCs. The DCs were
extensively washed after priming with 5 mg/ml soluble peptide or PSM/pep-
tides and either immediately co-incubated with B3Z cells (0 h) or cultured for
18–30 hr before T cell co-incubation.
Data are presented as mean ± SD. *p < 0.05, **p < 0.01. See also Figure S1.processing. Ironically, too strong TLR agonists may induce detri-
mental inflammatory responses (Spaner et al., 2008), which pre-
vents their use in the clinic. In addition to inflammatory cytokines,
type I interferons (IFN-Is) also promote DC maturation, antigen
cross-presentation, and CD8 T cell clonal expansion (Coffman
et al., 2010; Le Bon and Tough, 2008). Furthermore, a recent
study reported that IFN-I plays a pivotal role in anti-tumor immu-
nity by reactivating cross-presentation function in intra-tumor
DCs (Yang et al., 2014).958 Cell Reports 11, 957–966, May 12, 2015 ª2015 The AuthorsThe physical properties of antigens and adjuvants may con-
tribute to their immune-stimulating functions. The size, shape,
and surface characteristics of an antigen or adjuvant have a sig-
nificant impact on its immunogenicity (Bachmann and Jennings,
2010). A particulate antigen vaccine might provide an advantage
over the soluble antigen vaccine by serving as antigen depot and
protecting the antigen from enzyme degradation, enabling tar-
geted delivery to specific immune organs and cell types, and
stimulating antigen presentation via the desired pathways at a
controlled release rate (Paulis et al., 2013). For example, an
alum adjuvant and many nano-sized crystal structures can
activate inflammasome and promote IL-1b release in DCs,
which may facilitate the antigen-presentation function of DCs
and boost immune responses (Sharp et al., 2009). However,
the mechanism of action of these particles is still not well
understood.
Discoid porous silicon microparticles (PSMs, 1 mm in diameter
and 400 nm high) can carry nano-sized drugs and have been
used for delivery of small-molecule drugs and other cancer ther-
apeutics (Chen et al., 2014; Dave et al., 2014; Shen et al., 2013a;
Xu et al., 2013). This drug carrier is degradable and biocompat-
ible, and the rate of release of the cargo can be tailored by sur-
face chemical modification (Shen et al., 2013b; Tanaka et al.,
2010; Xu et al., 2013). Here, we explored the potential of PSMs
as an adjuvant for a cancer vaccine. PSMs loadedwith liposomal
antigen inside the nanopores were efficiently internalized by DCs
and trafficked to early endosomes for efficient cross-presenta-
tion. Notably, phagocytosis of PSMs induced IFN-I responses
in DCs. In addition, DCs primed with PSM-loaded HER2 antigen
peptide inhibited the growth of HER2-overexpressing mammary
gland tumors in mice by stimulating stroma cell major histocom-
patibility complex class II (MHCII) expression, Th1 cytokine pro-
duction, and intra-tumor CD8 T cell cytotoxicity.
RESULTS
Uptake of PSM-Loaded Antigen by DCs
We analyzed particle uptake by immune cells in mice treated
with intravenous (i.v.) injection of PSMs, and found that the par-
ticles were preferentially engulfed by CD11c+ DCs compared
with F4/80+ macrophages in the peripheral blood (Table S1).
Since DCs are themost efficient APCs, we explored the possibil-
ity of applying PSM to potentiate antigen presentation. We first
applied ovalbumin (OVA), a well-characterized model antigen,
for in vitro and in vivo immune response studies (Figure S1A).
Fluorescein isothiocyanate (FITC)-conjugated OVA (FITC-OVA)
was packaged into liposomes and loaded into PSMs according
to a previously described procedure (Shen et al., 2013a; Tanaka
et al., 2010; Xu et al., 2013). The PSM-loaded FITC-OVA (PSM/
FITC-OVA) was efficiently internalized by DCs as early as
0.5 hr after co-incubation in cell culture (Figure 1A), indicating
efficient cell uptake of particles. Transmission electron micro-
scopy revealed that the PSM particles were surrounded by
phagosome-like vesicular structures 3 hr after incubation (Fig-
ure 1B). Pretreatment of DCs with either the phagocytosis inhib-
itor cytochalasin D or the macropinocytosis inhibitor amiloride
significantly decreased particle internalization (Figures 1C and
1D), suggesting that both phagocytosis and macropinocytosis
Figure 2. Antigen Presentation of PSM-Loaded OVA
(A) Subcellular transport of antigen. DCs were incubated with PSM/FITC-OVA
for 0.5 hr and then washed extensively to remove unbound particles. The cells
were cultured for an additional 0.5 hr, 1 hr, 3 hr, or 6 hr before fixation, followed
by immunostaining with antibodies recognizing specific organelles (EEA1 for
early endosome, Rab7 for late endosome, TR for recycling endosome, and
KDEL for the ER). Scale bar, 25 mm.
(B) IL-2 production by B3Z cells after co-incubation with DCs treated with
100 mg/ml OVA or PSM/OVA in the presence of proteosome inhibitors (MG-132
and epoxomicin) or lysosome inhibitor (leupeptin). Peptide I (100 ng/ml) served
as the positive control.
(C) OVA cross-presentation by BMDCs. BMDCs were incubated with OVA or
PSM/OVA for 16 hr, harvested, and labeled with anti-CD11c antibody to
identify DCs and 25D1.16 antibody to identify the OVA257-264/H-2K
b complex
on the DC surface. The percentages of 25D1.16+ staining populations in DCs
are shown in red numbers.
Data are presented as mean ± SD. *p < 0.05, **p < 0.01. See also Figure S2.were involved in the process. Interestingly, real-time particle
tracking revealed that the DC-internalized particles could be
transferred to the neighboring cells in vitro (Figure S1D; Movie
S1). When PSM-containing DCs were intravenously injected
into mice, certain PSM particles parted from the injected cells
and likely were phagocytosed by the endogenous cells
(Figure S1E).
We next assessed the T cell response to antigen cross-pre-
sentation of PSM-loaded OVA (PSM/OVA) in DCs using an
in vitro antigen-presentation assay. DCs pulsed with PSM/
OVA induced significantly higher levels of IL-2 production inOVA-specific B3Z CD8 T cells than DCs pulsed with soluble
OVA (Figures 1E, 1F, and S1B), suggesting that cross-presenta-
tion of PSM/OVA was much more efficient than that of soluble
OVA in DCs. Efficient cross-presentation of PSM/OVA was not
dependent on the PSM size, as DCs pulsed with OVA in
different-sized PSM microparticles (0.6–2.5 mm in diameter)
consistently induced higher levels of IL-2 production in B3Z
cells than DCs pulsed with soluble OVA or liposomal OVA (Fig-
ure S1C). Consequently, we chose to use 1 mm PSM particles in
all further studies. We subsequently tested whether PSM pack-
aging could induce sustained antigen presentation. DCs were
pulsed with either soluble or PSM-packaged OVA peptide for
2 hr at 37C followed by extensive washing, and then were
either immediately co-cultured with B3Z cells or incubated in
medium for 18 or 30 hr before co-culture with B3Z cells. The
IL-2 levels in the T cell culture were comparable when DCs
were used for co-culture immediately after removal of OVA pep-
tide in either the soluble or PSM formulation (Figure 1G). How-
ever, T cell activities were significantly higher in co-culture
with PSM/peptide-pulsed DCs than with soluble peptide-pulsed
DCs at 18 hr and 30 hr after peptide removal, indicating that
PSM-delivered antigen induced prolonged MHC-peptide pre-
sentation to T cells.
Antigen Presentation Pathway of PSM/OVA Antigen
We next checked intracellular antigen trafficking by confocal mi-
croscopy. PSM/FITC-OVA particles colocalized with early endo-
somes (EEA1+) as early as 0.5 hr after co-incubation with DCs,
and were in the endoplasmic reticulum (ER) (KDEL+) at 3 hr
and 6 hr postincubation. Particles were rarely found in late endo-
somes (Rab7+) or recycling endosomes (transferring receptor+;
Figure 2A). Interestingly, PSM/FITC-OVA could still be spotted in
early endosomes by 6 hr, indicating that PSM/OVA was retained
in this subcellular organelle for a prolonged time. In comparison,
free FITC-OVA showed a very weak signal by 6 hr, likely due to
quick degradation inside the cells (data not shown).
To identify route(s) of antigen processing of the PSM-pack-
aged vaccine, we treated DCs with proteasome and lysosome
inhibitors before co-incubation with soluble OVA or PSM/OVA,
and measured induction of IL-2 expression. Proteasome inhibi-
tors (MG-132 and epoxomicin), but not the lysosome inhibitor
leupeptin, completely blocked class I antigen presentation of
soluble OVA (Figure 2B). In contrast, PSM/OVA-induced IL-2
production was inhibited by all inhibitors, suggesting that
both the proteasome and lysosome pathways were involved
in antigen presentation of PSM/OVA. Since the TAP protein is
an essential component of the class I antigen-presentation
pathway (Trombetta and Mellman, 2005), we tested antigen
processing in DCs isolated from TAP1 knockout mice (TAP/
DCs). As expected, class I antigen presentation of PSM/OVA
was abolished in TAP/ DCs (Figure S2A). In contrast, class
II antigen presentation of PSM/OVA was comparable between
wild-type (WT) and TAP/ cells (Figure S2B). Thus, PSM/OVA
cross-presentation by DCs requires TAP-dependent antigen
processing.
SinceOVA antigen processing resulted in surface expression of
OVA peptide-bound MHCI molecules, we probed the processed
antigen with 25D1.16 antibody, which specifically recognizes theCell Reports 11, 957–966, May 12, 2015 ª2015 The Authors 959
Figure 3. PSMs Induced IFN-I Signaling
in DCs
(A) Protein levels of proinflammatory cytokines in
culture media of BMDCs 24 hr after incubation
with PSM, free antigen, or PSM/antigen. Cell cul-
ture medium served as the negative control.
(B) Expression pattern of co-stimulatory mole-
cules on the surface of BMDCs 24 hr after incu-
bation with PSM.
(C) qPCR analysis of mRNA levels of the Ifn-a4 and
Ifn-b genes in BMDCs 5 hr after co-incubation with
PSM, free antigen, or PSM/OVA antigen.
(D) ELISA for IFN-b and RANTES in culture media
of BMDCs 24 hr after incubation with PSM.
Data are presented as mean ± SD. *p < 0.05, **p <
0.01. See also Figure S3.MHCI-peptide (SIINFEKL-H-2Kb) complex. Indeed, we identi-
fied more 25D1.16+ cells in PSM/OVA-primed DCs than in
soluble OVA-primed DCs (Figure 2C), thus confirming the
enhanced antigen processing and presentation of PSM-loaded
OVA by DCs.
These observations indicate that, after it is internalized by DCs
through phagocytosis/macropinocytosis, PSM/OVA leaves the
phagosome, and the released antigen is processed through
the proteasome pathway. The processed antigen then binds to
MHC molecules in the ER and is transported to the cell surface.
Alternatively, the antigen can be processed directly by endoso-
mal proteases in early endosomes and presented to the cell sur-
face in the form of an antigen peptide-MHC complex. In either
case, the TAP protein is required for loading of antigen peptide
onto MHC molecules (Figure S2C).
PSM-Induced Innate Immune Responses
We reasoned that the enhanced cross-presentation by PSM-
loaded antigen might be associated with activation of innate im-
munity in addition to early endosome delivery. Although an alum
adjuvant can activate inflammasome and induce IL-1b matura-
tion and release in DCs, PSMs did not induce IL-1b release in
lipopolysaccharide (LPS)-primed DCs (Figure S3A). Neither
PSMs nor antigen-loaded PSMs changed the mRNA or protein
levels of proinflammatory cytokines (Figures 3A and S3B). In
addition, there was almost no change in the expression of sur-
face co-stimulatory molecules (CD80, CD86, and CD40) after
PSM treatment (Figure 3B).
As one important arm of innate immune responses to viral
infection, the IFN-I response elicits optimal T cell activation by
promoting cross-presentation and stimulating CD8 T cell clonal
expansion (Le Bon and Tough, 2008; Ng and Gommerman,960 Cell Reports 11, 957–966, May 12, 2015 ª2015 The Authors2013).We analyzed the expression profile
of IFN-I-related genes and found that
both empty PSMs and antigen-loaded
PSMs, but not free antigen, induced a
significant increase in IFN-a4 and IFN-b
expression (Figure 3C). ELISA results
confirmed that PSM-treated DCs ex-
hibited a modest but significant increase
in IFN-b production, and also secreted ahigh level of RANTES, an IFN-I-regulated chemokine (Lapteva
and Huang, 2010; Figure 3D).
The PSM-Induced IFN-I Response Is Dependent on TRIF
and MAVS Signaling
To determine whether the IFN-I response elicited by PSM were
dependent on any known TLR- or RIG-I-like receptor (RLR)-
induced IFN-I pathways, we knocked down expression of key
adaptor molecules in these pathways and then analyzed
PSM-induced IFN-I responses in DCs (Figures 4A–4D). PSM re-
tained the ability to induce the IFN-I response with suppressed
expression of MyD88 and STING. In contrast, IFN-I induction
was abolished when TRIF or MAVS was knocked down, sug-
gesting that the PSMs induced the IFN-I response through
TRIF- and MAVS-dependent pathways. We next applied
bone-marrow-derived DCs (BMDCs) from gene knockout mice
to validate the results from small hairpin RNA (shRNA)-based
studies. IFN-I induction by PSMs was completely inhibited in
Trif/ BMDCs, but not in StingGt/Gt (Sauer et al., 2011) or
Myd88/ BMDCs (Figures 4E–4H). Consistently, PSM treat-
ment enhanced RANTES production in BMDCs from WT,
Myd88/, StingGt/Gt, and Tlr3/ mice; however, RANTES
production was inhibited in Trif/ BMDCs (Figure 4I). Although
TLR4, TLR9, and TLR3 deficiency abolished the DC response to
LPS, CpG, and polyI:C, respectively (Figure S4A), the PSM-
induced IFN-I response was not affected (Figure S4B), suggest-
ing a TLR-independent mechanism for PSM-induced IFN-I
responses.
Since PSM uptake and cross-presentation require phagocy-
tosis of PSM/antigen, we examined whether phagocytosis is
required for PSM-induced IFN-I. Pretreatment with the phagocy-
tosis inhibitor cytochalasin D suppressed IFN-I induction by
Figure 4. TRIF- and MAVS-Mediated PSM-
Induced IFN-I Activation
(A–D) PSM-induced changes of Ifn-a4 and Ifn-b
gene expression in BMDCs infected with lentivi-
ruses carrying shRNAs targeting the indicated
genes.
(E–H) PSM-induced changes of Ifn-a4 and Ifn-b
gene expression in BMDCs isolated from WT or
gene knockout mice.
(I) PSM-induced RANTES production in BMDCs
isolated from WT or gene knockout mice.
(J) Schematic view of the PSM-induced signaling
pathway that mediates IFN-I activation.
Data are presented as mean ± SD. *p < 0.05, **p <
0.01. See also Figure S4.PSM (Figure S4C). We also analyzed downstream kinase
signaling of phagocytosis. PI3K inhibition had no effect on IFN-
I induction (Figure S4D), whereas inhibition of the key kinases
(TBK1/IKKi) for IFN-I signaling by BX795 markedly inhibited
IFN-I induction (Figure S4E). We further analyzed the activation
status of MAPKs and NF-kB signaling in BMDCs after PSM/an-
tigen priming. Except for a slightly increased level of ERK phos-
phorylation, PSM priming did not strongly activate JNK, p38,
AKT, or NF-kB signaling (Figure S4F).
Taken together, these data show that phagocytosis of PSM-
loaded antigen by DCs activates TRIF- and MAVS-dependent
signaling and the downstream kinases TBK1/IKKi to elicit IFN-I
response (Figure 4J).
Anti-Tumor Efficacy of DCs Primed with PSM/HER2
Antigen Peptide
Given the critical role of efficient cross-presentation and CD8
T cell cytotoxicity in anti-tumor immunity, we next tested
whether enhanced cross-presentation and activated IFN-I
in DCs by PSM/antigen could be translated into enhanced
anti-tumor activity in animal tumor models. Balb/c mice were
inoculated with TUBO tumor cells, which were originally
derived from mammary gland tumors of Balb-neuT transgenicCell Reports 11, 957–9mice (overexpressing rat neu under the
MMTV promoter) (Lucchini et al., 1992).
When the tumors reached a palpable
size, the mice were treated intravenously
with PSMs, PSM/p66 (p66 is a class I
HER2 antigen peptide) (Nagata et al.,
1997), p66-primed DCs (DC+p66), or
PSM/p66-primed DCs (DC+PSM/p66).
Although the PSMs had no impact on tu-
mor growth, direct PSM/p66 administra-
tion inhibited tumor growth significantly
(Figure 5A). Mice that received DC+p66
showed tumor growth inhibition compa-
rable to that observed in the PSM/p66
treatment group. The most significant
effect was observed in mice treated
with DC+PSM/p66, as demonstrated by
nearly complete tumor growth inhibition
and extended animal survival (Figures5A and S5A). The effect on tumor growth was specific for
HER2 peptide p66, as treatment with DC only or DCs primed
with PSM/TRP-2 (a nonrelated antigen) could not inhibit tumor
growth (Figure S5B). In addition, the anti-tumor efficacy corre-
lated with intra-tumor HER2-specific CD8 T cell frequency
(Figure S5C). In a separate study, we evaluated the tumor-pre-
vention effect of PSM/p66. Balb-neuT mice started to develop
spontaneous tumors at 15 weeks, and all mice developed tu-
mors by week 17 (Figure S5D). On average, there were more
than five tumors per mouse by week 20 (Figure 5B). Mice treated
with PSM/p66 or DC+PSM/p66 developed significantly fewer
tumors and exhibited longer tumor latency than the nonvacci-
nated mice (Figures 5B and S5D). This result indicates that
PSM-loaded HER2 peptide served as an anti-HER2 vaccine
and preventedmammary gland tumor development in the trans-
genic mice.
PSM/Antigen-Primed DCs Elicited an
Immunostimulating Tumor Microenvironment
Since anti-tumor immunity is often dependent on the immune-
stimulating tumor microenvironment (Coussens et al., 2013),
we analyzed intra-tumor cytokine levels in posttreatment
TUBO tumors. Consistent with the cell-based study (Figure 3C),66, May 12, 2015 ª2015 The Authors 961
Figure 5. PSM/HER2 DC Vaccine Inhibited
Mouse Mammary Gland Tumor Growth
(A) Inhibition of primary TUBO tumor growth.
TUBO cells were inoculated into the mammary
gland fat pads of mice. After 4 days, the mice
(n = 8/group) were treated intravenously with
PBS, PSM, PSM/p66, DC+p66, or DC+PSM/
p66, and tumor growth was monitored over the
next 4 weeks. Tumor volume is presented as
mean ± SEM.
(B) Tumor multiplicity in Balb-neuT mice that
received different treatments. Balb-neuT trans-
genic mice were divided into three groups (n = 5)
and treated twice (weeks 6 and 8) intravenously
with the indicated agents. The number of tumor
nodules per mouse was counted on weekly basis.
(C–E) qRT-PCR measurement of the mRNA levels
of IFN-I, proinflammatory cytokines, and cytotoxic
T cell markers in tumor tissues from different
treatment groups.
(F and G) ELISA measurement of intra-tumor
cytokine levels in mice administered different
treatments.
Data are represented as mean ± SD except tumor
volume. *p < 0.05, **p < 0.01. See also Figure S5.quantitative RT-PCR (qPCR) analysis revealed significantly
increased intra-tumor IFN-I levels in vaccinated mice (Fig-
ure 5C). The levels of proinflammatory cytokines varied.
Although expression of TNF-a and IL-17A increased in the
vaccinated mice, IL-17F, IL-6, and the antiapoptotic molecule
Bcl-2 remained unchanged (Figure 5D). Expression of the anti-
gen-presentation molecule MHCII significantly increased in
vaccinated groups (Figure 5E). Moreover, the levels of cyto-
toxic T cell markers (granzyme and perforin) and IFN-g also
increased after vaccination, with granzyme and IFN-g levels
being 2- to 3-fold higher in the DC+PSM/p66 treatment group
than in the DC or DC+p66 treatment groups (Figure 5E). Inter-
estingly, all DC vaccines induced intra-tumoral expression
of the Treg marker gene Foxp3 (Figure S5E), suggesting
that vaccination induced Treg expansion and tolerance (Am-
brosino et al., 2006). To confirm the qPCR results, we isolated
single cells from tumor samples, grew them in culture, and
measured cytokine levels in cell growth media by ELISA.
We detected significantly increased levels of key proinflamma-
tory cytokines such as IL-1b, IL-17, and TNF-a in tumor
cells from the DC+PSM/p66 treatment group compared with
the other groups (Figure 5F). In addition, levels of Th1 cyto-
kines such as IFN-g, IL-12p40, and IL-12p70 were highest in
the DC+PSM/p66 treatment group (Figure 5G). As Balb/c
mice are prone to developing Th2 immune responses (Mills
et al., 2000), we observed a dramatic increase in level of the
Th2 cytokine IL-4 after DC and DC+p66 treatments (Fig-
ure S5F). However, DC+PSM/p66 treatment did not induce962 Cell Reports 11, 957–966, May 12, 2015 ª2015 The AuthorsIL-4 production. Thus, PSM/p66 priming
could obviate the strong Th2 response
associated with DC treatment in
Balb/c mice. These results suggest that
DC+PSM/p66 induced a proinflamma-tory environment in tumor tissues and shifted an otherwise pre-
dominant Th2 response in Balb/c mice to a Th1 response,
which may contribute to the anti-tumor immunity.
PSM/HER2-Primed DC Vaccine Activated Cytotoxic T
Cell Immunity against Tumor
We further analyzed intra-tumor cell populations that might
contribute to the intra-tumor cytokine milieu. Western blot anal-
ysis of tumor tissue lysates revealed comparable MHCI protein
levels among the treatment groups; however, MHCII expres-
sion dramatically increased in tumors from the DC+PSM/p66
group (Figure 6A). Immunohistochemical (IHC) staining con-
firmed a high level of MHCII+ cells on the edge of tumor nod-
ules in the DC+PSM/p66 group (Figure 6B). Immunofluorescent
staining and flow-cytometry analysis revealed a markedly
increased percentage of CD11c+MHCII+ cells in tumors from
the DC+PSM/p66 group compared with other groups (Figures
6C and 6D).
As the executor of T cell-mediated anti-tumor immunity,
HER2-specific CD8 T cells had the highest level in the
DC+PSM/p66-treated tumors (Figure 6E). To determine which
type(s) of immune cells were required for the anti-tumor immu-
nity, we depleted CD4 T cells, CD8 T cells, or macrophages in
mice bearing TUBO tumors, and then treated the mice with
DC+PSM/p66 (Figure 6F). CD8 T cell depletion completely
abolished anti-tumor immunity. In contrast, neither depletion of
CD4 T cells or macrophages nor treatment with an isotype con-
trol antibody impaired the anti-tumor immunity. These results
Figure 6. DCs Primed with PSM/HER2
Elicited CD8 T Cell-Mediated Anti-Tumor
Immunity
(A) Western blot analysis of MHCII protein levels in
TUBO tumor tissues from posttreatment Balb/c
mice. Tumor tissues were harvested 10 days after
treatment.
(B) Immunohistochemical staining of MHCII in
TUBO tumor tissues from posttreatment Balb/c
mice. Scale bar, 100 mm.
(C) Immunofluorescent staining of CD11c and
CD34 (vascular marker) in TUBO tumor tissues
from posttreatment Balb/cmice. Scale bar, 50 mm.
(D) Flow-cytometry analysis of CD11c+MHCII+
cells isolated from posttreatment TUBO tumor
tissues. The percentage of CD11c+MHCII+ cells in
each sample is labeled in red.
(E) Increased HER2-specific CD8 T cells in post-
treatment TUBO tumors. Left: flow-cytometry
analysis of CD8 and p66-pentamer+ tumor-infil-
trating lymphocytes in posttreatment tumor tis-
sues. Right: quantification of the percentage of
p66-pentamer+ CD8 T cells in total tumor cell
suspension.
(F) Effect of immune cell depletion on inhibition of
TUBO tumor growth by DC+PSM/p66 treatment.
Balb/c mice inoculated with TUBO tumor (n = 8/
group) were treated with a control isotype anti-
body, anti-CD4 antibody, anti-CD8 antibody, or
clodrosome to deplete specific cell types. Mice
were then treated with DC+PSM/p66 and tumor
growth was monitored over the next 4 weeks.
Tumor volume is presented as mean ± SEM.
Data are represented as mean ± SD, except for
tumor volume. *p < 0.05, **p < 0.01.indicate that CD8 T cells are essential for DC+PSM/p66-induced
anti-tumor activity.
DISCUSSION
It has been suggested that phagocytosis of particulate antigens
or adjuvants not only facilitates their uptake by APCs but also
triggers innate immune activation by interaction with innate im-
mune receptors (Fric et al., 2014). In the current study, we
demonstrated that phagocytosis was required for both cross-
presentation and IFN-I induction in PSM/antigen-primed DCs,
reinforcing the dual role of phagocytosis in antigen uptake and
innate immune activation.
The IFN-I response is elicited in DCs after exposure to micro-
bial or tumor-derived DNA and RNA. Binding of nucleotides ac-
tivates innate immune receptors such as TLRs and RLRs, and
subsequently recruits individual adaptor proteins and the key ki-
nases TBK1 and IKKi, leading to IRF3 or IRF7 phosphorylation,
nuclear translocation, and activation of IFN-I gene transcription
(Prinz and Knobeloch, 2012). It is generally accepted that
MyD88 is required for TLR7/8/9-induced IFN-I signaling, and
TRIF is needed for TLR3/4-induced IFN-I signaling. The intracel-lular RNA and DNA sensors rely on the adaptor molecules MAVS
and STING for signaling transduction (Prinz and Knobeloch,
2012). Interestingly, membrane fusion can directly activate the
IFN-I response through STING-dependent signaling without
activating DNA or RNA sensors, suggesting that physical fusion
sometimes serves as a ‘‘danger signal’’ to elicit an innate im-
mune response (Holm et al., 2012). However, it is unlikely that
membrane fusion is the primary factor in PSM-induced IFN-I re-
sponses, as knockdown or knockout of STING in DCs did not
abolish PSM-induced IFN-I response. It is intriguing that both
TRIF and MAVS are essential for PSM-induced IFN-I responses,
since they seem tomediate different upstream signals from TLRs
and RLRs. However, MAVS was initially identified as a down-
stream adaptor of TRIF in intracellular poly(I:C)-induced IFN-I
signaling (Xu et al., 2005), and both TRIF and MAVS are required
for DDX1/DDX21/DHX36 complex-induced IFN-I activation
(Zhang et al., 2011). Therefore, a TRIF-MAVS axis may exist for
IFN-I induction in response to intracellular DNA/RNA molecules
or phagocytosed PSM particles. Alternatively, the particulate
adjuvant may activate downstream signaling by altering mem-
brane lipid structures, as previously reported for alum (Flach
et al., 2011). Thus, further studies are warranted to elucidateCell Reports 11, 957–966, May 12, 2015 ª2015 The Authors 963
the mechanism underlying PSM activation of IFN-I signaling. It is
noteworthy that PSMs induced amoderate level of IFN-I expres-
sion. Such a level of IFN-I is sufficient to stimulate cross-presen-
tation and CD8 T cell expansion, as previously demonstrated for
lymphotoxin receptor-mediated IFN-I induction (Summers de-
Luca et al., 2011).
In the context of the tumormicroenvironment, although endog-
enous immunity against cancer still exists, many aspects of anti-
tumor immunity are crippled during tumor development and thus
require an exogenous boosting treatment (Gajewski et al.,
2013a). Increased levels of IFN-I have been reported to correlate
favorablywith clinical immune responses against cancer (Fuertes
et al., 2011), and intra-tumor IFN-I levels were shown to predict
the clinical responses of breast cancer patients to anthracy-
cline-based chemotherapy (Sistigu et al., 2014). Exogenous ther-
apeutic antibody coupled with IFN-b also enhances anti-tumor
activity by activating the cross-presentation capacity of endoge-
nous DCs (Yang et al., 2014). Therefore, targeting DCs and reac-
tivating their cross-presentation capacity is a promising strategy
for cancer immunotherapy. DC-based immunotherapy can be
achieved by administration of exogenously prepared DCs or in-
jection of antigen and adjuvants targeting endogenous DCs.
Mechanistically, injected DCs may present antigen directly to
T cells, or serve as a cellular delivery vector and transfer the anti-
gen to endogenous DCs (Kleindienst and Brocker, 2003; Yewdall
et al., 2010). It is tempting to speculate that PSM/antigen-loaded
DCsmay transfer PSM/antigen to endogenousDCs andpromote
their anti-tumor immunity. Our data support such a scenario, as
we observed intercellular exchange of PSMs between DCs
in vitro, and PSMs released from injected DCs in vivo.
Previous reports also identified anti-tumor immunity accom-
panied by increased intra-tumoral MHCII expression after treat-
ment with the agonist anti-CD40 antibody, which was attributed
to activated innate immune cells (mainly macrophages) (Beatty
et al., 2011; O’Sullivan et al., 2012). In the current study, PSM/an-
tigen-primed DC treatment also drastically increased MHCII
expression in tumor tissues. However, depletion of macro-
phages in the TUBO tumor model did not have a significant
impact on the DC-based therapeutic effect. Instead, increased
tumor infiltration of CD11c+ cells accompanied by MHCII upre-
gulation was observed in mice treated with PSM/HER2-primed
DCs, demonstrating the critical role of activated DCs in anti-tu-
mor activity. These findings are in line with a recent report that
described activation of intra-tumoral DCs by IFN-I and enhanced
antibody-mediated tumor immunity (Yang et al., 2014).
CD8 T cells are regarded as the key player in anti-tumor activ-
ity (Dougan and Dranoff, 2009). We have shown that depletion of
CD8 T cells abrogates the anti-tumor activity of a PSM/antigen-
primed DC vaccine. This result is in line with previous reports that
used the sameCD8 epitope HER2 peptide and showed that anti-
tumor immunity is mainly dependent on CD8 T cell cytotoxic
killing activity (Assudani et al., 2008; Nava-Parada et al., 2007).
Another important observation is that vaccination also induces
FOXP3 expression in tumor tissues. Treg infiltration is a major
barrier against inducing effective anti-tumor immune responses
both in human clinical trials (Gajewski et al., 2013b) and inmurine
tumor models such as Balb-neuT transgenic mice (Ambrosino
et al., 2006). Transient Treg ablation by antibody or genetic964 Cell Reports 11, 957–966, May 12, 2015 ª2015 The Authorsmanipulation has shown an anti-tumor effect by itself (Bos
et al., 2013; Marabelle et al., 2013). This may explain why CD4
antibody depletion did not affect the anti-tumor immunity of
DCs primed with PSM/antigen, as CD4 antibody may also
deplete Tregs in addition to T helper cells. Based on the current
study, we suggest that a combined treatment with PSM/antigen-
primed DC vaccine and transient Treg ablation may further
improve the outcomes of anti-tumor vaccines.
In conclusion, we have shown that PSM/antigen-primed DC
vaccination produced a strong anti-tumor immunity by inducing
efficient antigen cross-presentation and eliciting an IFN-I
response. Phagocytosis of PSM/antigen generated prolonged
early-endosome antigen localization and simultaneously acti-
vated IFN-I signaling, thus providing another example of how
phagocytosis and innate immune signaling cooperate to
enhance cross-presentation. We also revealed a specific intra-
cellular pathway that mediates PSM-induced IFN-I signaling,
illustrating the essential functions of TRIF andMAVS in response
to particulate antigen. In addition, we demonstrated the role of
an immunocompetent tumor microenvironment in a PSM-poten-
tiated DC vaccine. These findings further highlight the advan-
tages of a particulate vaccine and the role of IFN-I signaling in
stimulating the tumor immune microenvironment for successful
immunotherapy.
EXPERIMENTAL PROCEDURES
Mice
Balb-neuT transgenic mice were kindly provided by Dr. Guido Forni (University
of Torin) and Dr. Larry Pease (Mayo Clinic). C57BL/6 and Balb/c mice were or-
dered from Charles River or The Jackson Laboratory. B6.129S2-Tap1tm1Arp/
J (TAP/), B6N.129S1-Tlr3tm1flv/J (Tlr3/), C57BL/6J-Tmem173gt/J
(StingGt/Gt) mouse lines were ordered from The Jackson Laboratory. Tlr4/,
Tlr9/, Trif/, and Myd88/ mouse lines were maintained as previously
described (Duggan et al., 2011; Millien et al., 2013). All animal experiments
were approved by the Houston Methodist Research Institute IACUC.
Preparation of Antigen-Encapsulated Liposomes and Loading into
PSMs
Liposomes were made as previously described (Tanaka et al., 2010; Xu
et al., 2013). Briefly, protein or peptide antigen was dissolved in H2O, 1,2-dio-
leoyl-sn-glycero-3-phosphocholine (DOPC) was prepared in t-butanol at
20 mg/ml, and 0.1% Tween-20 was prepared in water. They were then mixed
together in t-butanol by vortexing for 1 min. The samples were then freeze-
dried in a lyophilizer. To load the liposomes into PSM particles (1 mm in diam-
eter and 400 nm high), 120 ml H2Owas added to liposome powder, followed by
a brief sonication. The liposomes in H2Owere then added to dry PSMparticles,
followed by a brief sonication.
In Vitro Antigen-Presentation Assay
An in vitro antigen-presentation assay was performed as previously described
(Mukai et al., 2011). Briefly, DC2.4 cells or BMDCs isolated fromC57BL/6 mice
or TAP/mice were seeded in a 96-well, flat-bottom culture plate at a density
of 23 105 cells/well and cultured for 12 hr at 37C. Eachwell waswashed once
with PBS and then the cells were pulsed with soluble OVA, PSM/OVA, OVA-
derived MHCI epitope peptide (OVA257–264; SIINFEKL), or MHCII epitope
peptide (OVA323-339; ISQAVHAAHAEINEAGR; Peptide 2.0) for the indicated
times and immediately fixed with 1% paraformaldehyde. The cells were then
co-cultured with 2 3 105 B3Z cells or 2 3 105 DOBW cells for 18 hr at 37C.
The response of stimulated B3Z or DOBW cells was assessed by determining
the amount of IL-2 that was released into the culturemedium using amurine IL-
2 ELISA kit (Ebioscience). For the inhibition assay, BMDCs were pretreated
with 10 mM of MG-132, 1 mM of epoxomicin, or 40 mM leupeptin (all from
EMD Chemicals) for 1 hr at 37C before antigen pulsing. The antigen-pulsing
media also contained each inhibitor.
Confocal Laser Scanning Microscopy
DC2.4 cells or BMDCs were seeded on eight-well chamber slides at a density
of 1 3 105 cells/well and cultured for 24 hr at 37C. Each well was washed
twice with PBS and the cells were pulsed with FITC-OVA or PSM/FITC-
OVA for 20 min. The cells were washed twice with PBS and incubated for
an additional 30 min, 1 hr, 3 hr, or 6 hr in culture media at 37C. The cells
were then washed with PBS, fixed with 4% paraformaldehyde, and stained
with antibodies against specific markers of individual organelles. The
following antibodies were used to detect the early endosome, late endosome,
early and recycling endosome, and ER, respectively: rabbit anti-EE Ag 1
(EEA1, ab74906; Abcam), rabbit anti-Rab7 (ab50313; Abcam), rat anti-trans-
ferrin receptor (TfR, ab22391; Abcam), and rabbit anti-KDEL (ab50601;
Abcam). The cells were then washed with PBS and incubated with Alexa
594-conjugated anti-rabbit IgG antibody (A11037; Invitrogen) or Alexa 594-
conjugated anti-rat IgG antibody (A21209; Invitrogen) for 1 hr at room temper-
ature. The samples were embedded with Prolong Gold antifade reagent
with DAPI (Invitrogen) and analyzed by confocal laser scanning microscopy
(Olympus IX81).
Real-Time PCR
TotalRNAwas isolatedwithTrizol reagent (Life Technologies) andused for cDNA
synthesiswith a reverse transcription kit (Roche). Real-timePCRwas performed
with SYBR Green Select Master Mix on a StepOnePlus Real-Time PCR system
(LifeTechnologies). Theexpressionof individual geneswascalculatedbyusinga
DDCT method and normalized to the expression of b-actin.
Cytokine Measurement
Cytokine release from tumor cells or splenocytes was measured by using the
Bio-Plex Pro Mouse cytokine 23-plex assay (Bio-Rad) or individual cytokine
ELISA kits from Ebioscience or PBL Assay Science.
shRNA-Mediated Gene Knockdown
The pLKO.1 lentiviral vectors encoding shRNAs were described previously
(Zhang et al., 2011) and purchased from Sigma. To produce lentiviral particles,
the lentiviral vectors were transfected into HEK293T cells along with the pack-
aging plasmids psPAX2 and pMD2. DCs were infected with the lentiviruses as
previously described (Zhang et al., 2011), and knockdown efficiency was
confirmed by real-time PCR.
Tumor Studies
TUBO cells (1 3 106 cells/mouse) suspended in cold Matrigel/PBS (1:1) were
implanted into themammary gland fat pads of female Balb/cmice (6–10weeks
old). On day 4 after tumor inoculation (when tumors had reached a palpable
size), the animals were randomly divided into groups (eight mice per group)
and received i.v. injections of treatments. The mice were then monitored for
survival and tumor size. Tumor volume was recorded as width 3 length2/2.
For intra-tumor cytokine and protein analysis, mice were sacrificed on day
14 after tumor inoculation, and the tumors were harvested for immune cell
typing and RNA and protein analysis by flow cytometry, qPCR, and western
blot analysis, respectively. In the tumor-prevention experiment with Balb-
neuT mice, groups of mice (five mice per group) were treated by i.v. injection
of vaccines at 6 and 8weeks of age, and then tumor incidence, tumormultiplic-
ity, and mouse survival was monitored for 30 weeks. In the depletion experi-
ments, anti-CD4 (GK1.5) and anti-CD8 (2.43) monoclonal antibodies (mAbs)
were used for in vivo depletion of T cell subsets. Clodrosomes (Encapsula
NanoSciences LLC) was used to deplete macrophages. Animals were injected
i.p. with 200 mg of anti-CD4 and anti-CD8 mAb or 200 ml of clodrosomes twice
per week for 3 weeks, starting 1 week before inoculation of the tumor cells (0.5
3 106 cells per mouse).
Statistical Analyses
Statistical significance was determined by using Student’s t test, and p < 0.05
was considered significant. For survival analysis, the log rank test was used to
compare Kaplan-Meier survival curves.SUPPLEMENTAL INFORMATION
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